Overview

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with paclitaxel.
Phase:
Phase 1
Details
Lead Sponsor:
OncoMed Pharmaceuticals, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel